Cefimix

Selected form

Cefixime

Method of action: Antibacterial Broad Spectrum (Bactericidal), Bactericidal

Treatment option: Bronchitis, Upper Respiratory Infection, Gonorrhea, Influenza, Infection, Infection,Urinary Tract, Middle Ear Infection, Pneumonia, Tonsillitis, Pharyngitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefimix

Quick Facts

Property	Description
Active ingredient	Cefixime
Form	Oral (Tablet, capsule, powder for suspension)
Pharmacological class	Third-generation cephalosporin, beta-lactam antibiotic
Common use	Systemic anti-infective agent (e.g., respiratory and urinary tract support)
Origin	Synthetic compound

What Type of Medicine is Cefimix?

Cefimix is a synthetic, prescription-only pharmaceutical preparation whose primary constituent is the active ingredient, Cefixime. It is chemically categorized as a third-generation cephalosporin, belonging to the broader family of beta-lactam antibiotics used for systemic use.

This classification as a third-generation cephalosporin is clinically recognized for providing enhanced stability against bacterial defense mechanisms known as beta-lactamase enzymes, which is a key differentiating factor compared to older-generation agents. As a bactericidal agent, its core function is to actively kill susceptible bacteria, rather than simply inhibit their growth. Cefixime is included on the World Health Organization's (WHO) Model List of Essential Medicines, recognizing its importance in global health systems for managing specific bacterial concerns.

Cefimix Composition and Forms: Oral Antibiotic

The medication is a single active ingredient product, containing only Cefixime combined with necessary pharmaceutical excipients, and is prepared for oral administration. Cefimix is typically supplied in multiple dosage forms, most commonly as a tablet, a capsule, or a liquid-based powder for oral suspension. This suspension form is a differentiating factor that supports effective delivery for pediatric use, as confirmed by clinical practice guidelines.

The availability of Cefimix in oral dosage forms allows for convenient systemic use in both adults and pediatric patient groups. Pharmacological studies support that its oral formulation is efficiently absorbed into the bloodstream via the gastrointestinal tract, enabling its widespread distribution throughout the body to target the infection source.

The General Purpose of Cefixime

The general purpose of Cefixime is to serve as an anti-infective agent by disrupting the structural integrity of harmful bacteria that cause infection. This function is achieved by interfering with the vital process of bacterial cell wall synthesis, a structural requirement for bacterial survival and replication.

By stopping the bacteria from successfully building and repairing their protective outer layer, Cefixime causes the microbial cells to break down and die. This bactericidal mechanism provides the essential benefit of enabling the body to clear out the invading pathogens, helping to resolve the underlying bacterial process in areas such as the respiratory or urinary tract.

Regulatory References

What side effects are possible with Cefimix?

Possible Side Effects and Safety Information

The regulatory safety profile for Cefimix (Cefixime) outlines documented adverse reactions based on clinical studies and post-marketing surveillance, classified by frequency and affected body systems. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.

Frequency-Classified Adverse Reactions

The most frequently reported effects involve the Gastrointestinal system, often listed as Very Common or Common in regulatory documents. Other systems are also documented to be affected across different frequency tiers, according to official labeling.

System-Organ Class	Common Adverse Reactions	Uncommon Adverse Reactions
Gastrointestinal	Diarrhea, Nausea, Abdominal pain	Vomiting, Flatulence
Nervous System	Headache	Dizziness, Vertigo
Skin/Subcutaneous Tissue	—	Rash, Pruritus (Itching)

Serious Adverse Reactions and Safety Constraints

The regulatory label documents the possibility of several clinically important, though rare, Serious Adverse Reactions. These include severe systemic effects such as Anaphylactic/Anaphylactoid Reactions (a life-threatening allergic reaction), Acute Renal Failure, Convulsions, and severe skin disorders like Stevens-Johnson Syndrome (SJS). The risk of Pseudomembranous Colitis (severe diarrhea caused by C. difficile) is also documented, and its onset may occur during or after therapy.

Safety notes specify that the medicine is restricted for use in individuals with a known hypersensitivity to Cefixime or any Penicillins or Cephalosporins due to the risk of cross-hypersensitivity. Furthermore, the official label includes considerations for patients with impaired renal function and older adults, noting the increased risk of adverse effects if kidney clearance is reduced.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Cefimix (Cefixime) overdose is defined by the potential for central nervous system (CNS) toxicity and specific emergency actions required when excessive quantities are ingested.

Documented Overdose Manifestations

Ingestion of large quantities may present with severe neurological effects, primarily the risk of encephalopathy. Clinical signs documented in regulatory sources include convulsions (seizures), confusion, impairment of consciousness, and movement disorders.

This risk of CNS toxicity is noted to be amplified in patients with pre-existing renal impairment in the event of an overdose.

Required Emergency Actions

Element	Official Regulatory Statement
Antidote	No specific antidote exists for Cefixime overdosage.
Supportive Treatment	Symptomatic treatment must be initiated. Procedures like gastric lavage may be indicated.
Action for Seizures	The drug must be discontinued, and anticonvulsant therapy can be administered if seizures occur.
When to Seek Help	Immediate medical attention is required for symptoms such as confusion, seizures, or impairment of consciousness.

Regulatory documents establish that management focuses on supportive care for the documented manifestations, and procedures such as hemodialysis are not considered effective for removing substantial drug quantities.

Therapeutic Uses of Cefimix

What Cefimix Treats: Main Uses and Benefits

Cefimix (Cefixime) is an oral systemic anti-infective agent generally applied across several clinical domains where bacterial pathogens may be the underlying cause of acute illness, focusing on symptom relief and supportive care. It is considered relevant in adult and pediatric patient populations (six months and older) for use across specific therapeutic domains, including uncomplicated Urinary Tract Infections (UTIs), Otitis Media (middle ear infection), pharyngitis, and acute exacerbations of chronic bronchitis. It is also relevant for managing specific enteric infections like Typhoid Fever and uncomplicated genitourinary infections like Gonorrhea.

Managing Acute Discomfort and Inflammation

This medication is commonly used when symptoms related to inflammatory or irritative states intensify and supportive relief is needed, particularly for infections in the respiratory tract and the ear. It assists with maintaining functional stability by managing symptoms that interfere with daily comfort, such as ear pain and symptoms related to systemic imbalance, including fever. The therapy may assist in easing symptoms that cluster into patterns of painful urination (dysuria) in UTIs or inflammation-driven earache in otitis media.

Addressing Systemic Symptom Burden

Cefimix is relevant in contexts involving heightened systemic burden, such as managing specific infections that lead to a widespread acute response. It assists with maintaining a sense of stability when symptoms are more noticeable, especially those associated with significant symptomatic burden, contributing to easing the overall symptom load during difficult episodes.

Quick Fact: Therapeutic Use
Symptom Relevance	Relevant for easing symptoms related to inflammatory or irritative states, such as dysuria and fever.
Condition Context	Used in conditions presenting with acute episodes, including UTIs and certain respiratory tract infections.
Clinical Scenario	Applied in clinical settings that involve acute or unstable symptom patterns requiring supportive relief.

Regulatory References

NIH DailyMed drug information for CEFIXIME

Eligibility and Restrictions for Use

Who Can and Cannot Use Cefixime

Official regulatory information defines the populations eligible and non-eligible for Cefixime use. This information is based strictly on government-issued prescribing labels and monographs.

Absolute Exclusions (Contraindications)

Cefixime must not be used by patients with a documented allergy or known hypersensitivity to Cefixime itself, or to any other medicine in the cephalosporin class. Use is also contraindicated for individuals who have experienced a severe or immediate hypersensitivity reaction to penicillins or other beta-lactam antibiotics due to the risk of cross-allergenicity. Additionally, the chewable tablet formulation is strictly contraindicated for patients with Phenylketonuria (PKU) as it contains phenylalanine.

Conditional or Restricted Use

Use is restricted and requires careful consideration for several populations:

Population/Condition	Eligibility Status & Constraint
Infants under six months of age	Safety and efficacy have not been established (use is not recommended).
Impaired Renal Function (e.g., severe)	Use is permitted, but requires dose adjustment and close monitoring.
Pregnancy	Use only if clearly needed (Category B in US labeling).
Breastfeeding	Consideration should be given to temporarily discontinuing nursing during treatment.

Patients with a history of gastrointestinal disease, particularly colitis, or a history of severe cutaneous adverse reactions must also use Cefixime with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Cefimix (Cefixime) based on its effects on renal clearance and potential pharmacodynamic effects on coagulation. This information is presented at a high-level, strictly aligned with prescribing labels.

Documented Drug Interactions

Interacting Substance	Officially Documented Interaction Outcome
Probenecid	Co-administration leads to a documented increase in Cefixime plasma levels due to competition for active renal tubular secretion.
Oral Anticoagulants (e.g., Warfarin)	Associated with a reported fall in prothrombin activity or an increase in prothrombin time.
Carbamazepine	Co-administration has been reported to result in elevated plasma concentrations of Carbamazepine.

Mechanism of Action

How Cefimix Works

Cefimix (Cefixime) is a beta-lactam molecule that initiates a mechanistic cascade through the inhibition of structural pathways in bacterial cells. Its mechanism involves interference with the process of cell wall synthesis.

Key Mechanism: Disrupting Bacterial Cell Wall Integrity

Cefimix acts on specific enzymes called Penicillin-Binding Proteins (PBPs), which are required for the construction of the bacterial cell wall. By binding covalently to and inactivating these transpeptidase enzymes, Cefimix prevents the final cross-linking step of the peptidoglycan layer. This molecular interaction results in an incomplete and structurally compromised cell wall.

Pathway Effect: Loss of Osmotic Regulation

This disruption triggers a cascade in which the faulty cell wall structure is unable to withstand the high internal pressure, or osmotic gradient, established by the bacterial cytoplasm. This failure in the structural integrity pathway leads to the swelling and rapid lysis (rupture) of the bacterial cell membrane, completing the mechanistic sequence.

Dosage and Administration Information

How Cefimix is Used: Official Administration Guidelines

Cefimix (Cefixime) is strictly an oral medicine, with the route of administration limited to swallowing. It is available in various official forms, including tablets, capsules, and a powder for oral suspension. The medication is generally taken without regard to food.

Standard Dosage and Frequency

The standard adult daily dose for most approved conditions is 400 mg, administered either as a single dose once daily or in two divided doses of 200 mg every 12 hours. For uncomplicated gonococcal infections, the official guidance specifies a single 400 mg oral dose.

Patient Group	Standard Daily Dose / Regimen
Adults	400 mg daily or 200 mg every 12 hours
Pediatric (6 months+)	8 mg/kg body weight daily (single or divided dose)

Form Specificity and Course Duration

For certain infections, such as Otitis Media, the oral suspension or chewable tablets should be used over conventional forms due to differences in absorption. The oral suspension powder must be reconstituted with water and shaken well prior to each dose. The typical treatment course is 7 to 14 days, but infections caused by Streptococcus pyogenes require a minimum course of 10 days. If a dose is missed, it should be taken as soon as possible unless it is near the next scheduled time, and doses should not be doubled.

Dose Adjustments

Official instructions mandate a dose reduction for patients with renal impairment. When creatinine clearance is le 60 mL/min, the dosage must be adjusted down to 300 mg or 200 mg daily, depending on the severity of impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Cefimix

## Evidence for Use in Uncomplicated Urinary Tract Infections (UTIs)

Research exploring the use of Cefimix for uncomplicated UTIs primarily involves Randomized Controlled Trials (RCTs) and various comparative studies, often including both non-pregnant adults and children. These studies were used in research exploring how symptoms change over time. The main study outcomes that research examined were the microbiological cure (clearance of the responsible bacteria from the urine) and the clinical resolution of symptoms, such as painful urination (dysuria), over short, defined time intervals.

Findings from trials generally described patterns of bacterial clearance and measurements of clinical outcomes, such as changes in symptoms, at the end of the treatment course. A topic for continued study relates to establishing the optimal short-term duration, as follow-up durations were limited, often only capturing phases of heightened symptom activity.

## Evidence for Use in Acute Otitis Media (Middle Ear Infection)

The evidence base for using Cefimix in Acute Otitis Media (AOM) mostly consists of older, pivotal comparative Randomized Controlled Trials (RCTs). These studies primarily focused on the pediatric population, and research examined outcomes related to physical discomfort, such as ear pain and fever, relevant in trials assessing short-term or episodic symptom patterns.

The studies explored various measures of clinical response, including the observed changes in ear symptoms and the reported bacteriological eradication rates obtained from middle ear fluid cultures. Evidence quality varies across studies, and long-term outcomes are not consistently well characterized.

## Evidence for Use in Other Specific Acute Infections

Cefimix was also evaluated in research for other specific acute conditions. For uncomplicated Gonorrhea, research examined the outcome of microbiological cure following a single dose. Older trials reported measurements of clearance rates; however, evidence quality varies across studies. Findings were heterogeneous when results were assessed against those of injectable treatments, and ongoing surveillance programs have indicated a decline in bacterial susceptibility, meaning certainty remains low regarding its current place in the evidence landscape.

## What is Still Uncertain About Cefimix Research

The evidence highlights what is known—and what is still uncertain. A key limitation is the age of some pivotal Randomized Controlled Trials (RCTs), as the activity of any antibiotic must be continually reassessed against evolving worldwide bacterial resistance. Comparative evidence is lacking for several common patient subgroups, and data for certain comorbidity groups remain insufficient. The study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cefimix (FAQ)

Q: What does Cefimix treat besides general infections?

According to official regulatory documents, Cefimix (Cefixime) is indicated for specific types of bacterial infections. These include acute exacerbations of chronic bronchitis, uncomplicated urinary tract infections, and middle ear infections (otitis media). The medicine is also approved for use in pharyngitis/tonsillitis and uncomplicated gonorrhea.

Q: Does Cefimix interact with vitamins or supplements?

Official product information does not explicitly list common vitamins or dietary supplements as substances that directly interact with Cefimix. However, regulatory guidance includes the recommendation that patients inform their healthcare provider about all concomitant medications, including vitamins, herbs, and supplements.

Q: Is it true that Cefimix can make some people feel tired?

While the most common documented adverse effects are gastrointestinal, general tiredness or weakness has been reported in post-marketing surveillance data. This effect is generally not listed among the Common adverse reactions, such as diarrhea or nausea, in the official safety profile.

Q: Does Cefimix affect birth control pills?

Official label information notes this interaction and advises patients about the potential for reduced effectiveness of hormonal contraceptives, such as birth control pills. This reduction in effectiveness is associated with an increased risk of unintended pregnancy or breakthrough bleeding.

Q: Is Cefimix known to cause any long-term side effects?

Official safety data describes the possibility of delayed side effects, such as Clostridium difficile-associated diarrhea (CDAD). This severe form of diarrhea can occur even up to two months after the medicine has been stopped. Regulatory documents do not specifically define or address effects that are permanent or chronic beyond this delayed onset.

Q: What should I do if a side effect of Cefimix is severe?

Regulatory documents describe signs of a severe or life-threatening reaction (such as facial swelling, tongue or throat swelling, difficulty breathing, or bloody stools) and state that these events require immediate emergency medical attention. This information is based on the documented potential for rare but serious adverse reactions.

Q: What kinds of tests are recommended before starting Cefimix?

Official guidelines describe that a review of prior immediate allergic reactions is necessary before Cefimix is administered. This review includes hypersensitivity reactions to cephalosporin antibiotics or to penicillin-class antibiotics, due to the documented risk of cross-allergenicity.

Q: Does Cefimix impact gut bacteria?

Official regulatory information indicates that Cefixime, as an antibiotic, is associated with an alteration of the normal bacterial flora within the colon. This alteration can sometimes permit the overgrowth of harmful bacteria, specifically C. difficile, which is the cause of pseudomembranous colitis.

Q: Does Cefimix have a warning about driving or operating machinery?

Official product labels do not contain a direct, mandatory warning against driving while using this medication. However, the official label documents adverse effects such as dizziness, vertigo, and headache, which are conditions known to be associated with impaired ability to operate machinery or vehicles.

Q: Can Cefimix affect glucose levels?

Official drug documents state that Cefimix can interfere with certain diagnostic tests. Specifically, it may cause false-positive results for glucose in the urine when using copper-reduction methods, but there is no specific information provided regarding its direct effect on blood sugar levels.

Q: Can Cefimix affect liver function?

Adverse reactions reported in regulatory documents include changes to markers of liver function. These have included transient elevations in liver enzymes (like SGPT and SGOT) and alkaline phosphatase, and documented cases of hepatitis and jaundice.

Q: Is Cefimix considered a 'broad-spectrum' antibiotic?

Yes, according to official regulatory-aligned clinical texts, Cefixime is classified as a broad-spectrum antibiotic. Its chemical structure as a third-generation cephalosporin gives it activity against a spectrum of bacteria.

How should Cefimix be stored and disposed of?

How to Store and Dispose of Cefimix?

Cefimix's storage requirements depend on its physical form. Solid dosage forms (tablets, capsules) must be kept at controlled room temperature (20 C to 25 C), protected from excess heat and moisture, and secured in their original, tightly closed container. The powder for oral suspension requires room temperature storage before mixing.

Once reconstituted, the liquid suspension is stable for 14 days when stored at room temperature or refrigerated (2 C to 8 C). It must not be frozen and should be shaken well before each use. Any unused portion of the suspension must be discarded after 14 days.

All forms must be stored out of the sight and reach of children to prevent accidental ingestion. Unused or expired medication should be disposed of through a medicine take-back program. If one is unavailable, dispose of it by following official guidelines for mixing it with an unappealing substance and placing it in the household trash; do not flush.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.